Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GYS1 | P13807 | 8/20 | 0.68 |
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1756390 | 0.88 | GYS1 (0.82) | GYS1MRGPRX4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1756451 | 0.83 | GYS1 (0.69) | GYS1MRGPRX4FFAR1PPARD | |
| SCHEMBL1756438 | 0.81 | GYS1 (1.00) | GYS1 | |
| SCHEMBL1756426 | 0.80 | GYS1 (0.79) | GYS1MRGPRX4 | |
| SCHEMBL1756363 | 0.78 | GYS1 (0.81) | GYS1MRGPRX4FFAR1RAB9ASMN1; SMN2 | |
| SCHEMBL1542780 | 0.76 | GYS1 (0.74) | GYS1MRGPRX4FFAR1RAB9ASMN1; SMN2 | |
| SCHEMBL1756401 | 0.75 | GYS1 (0.63) | GYS1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1756352 | 0.72 | MRGPRX4 (0.51) | GYS1MRGPRX4NPC1ALDH1A1MAPT | |
| SCHEMBL1756436 | 0.72 | GYS1 (0.60) | GYS1MRGPRX4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1756379 | 0.71 | GYS1 (0.53) | GYS1MRGPRX4FFAR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039495-B2 | Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators | HOFFMAN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-20110118322-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-19 | — | — | US | claimed |
| WO-2011058154-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | claimed |
| US-8039495-B2 | Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators | HOFFMAN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039495-B2 | Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators | HOFFMAN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039495-B2 | Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators | HOFFMAN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110118322-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-19 | — | — | US | disclosed |
| US-20110118322-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-19 | — | — | US | disclosed |
| WO-2011058154-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058154-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118322-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118322-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | GYS1 2/4885MRGPRX4 3745/4885FFAR1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.